ClinicalTrials.gg
WithdrawnNCT00255268Updated Aug 28, 2007

CMAB vs IMAB in Metastatic Prostate Cancer

A Phase 4 interventional study of Goserelin and Bicalutamide in Metastatic Prostate Cancer, sponsored by AstraZeneca. Withdrawn at 2 sites in Mexico. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-08-28.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing goserelin in Prostatic Neoplasms — 3 open to participants now, 4 under way, 3 of them phase 3. Goserelin · Prostatic Neoplasms.

Planned enrollment
25th of 29
15 · median 110
Started
2004
the only one that year
Phase 4
4 of 31
none open now
Registered
6th of 31
by date
Lead sponsor
2 of 31
AstraZeneca

Among the 31 studies testing goserelin in Prostatic Neoplasms, this one is the 25th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2004, is one of 4 in phase 4, and was the 6th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 31 studies testing goserelin in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing goserelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of D2 of Adenocarcinoma,
  • Naivety to treatment
  • Valuable bone

Exclusion criteria

Exclusion Criteria:

  • Hematological, liver or renal toxicity Grade IV
  • Severe and active infections
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to progression

Secondary outcomes

  1. Safety

  2. Quality of Life

07

Study locations

2 sites
  • Research Site
    Metepec, Mexico
  • Research Site
    Mexico City, Mexico
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00255268
Lead sponsor
AstraZeneca
First posted
Nov 18, 2005
Start date
Aug 2004
Last update
Aug 28, 2007

Study contacts

AstraZeneca Mexico Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Goserelin · Bicalutamide

Start the discussion